BRD4 and hematologic disorder: CPI-0610 demonstrates superior pharmacological properties compared to JQ1, an earlier BRD4 inhibitor (Mirguet et al., 2013) and is currently undergoing clinical development with a manageable safety profile for hematologic malignancies, particularly myelofibrosis (Albrecht et al., 2016; Sun et al., 2020; Stein et al., 2024; Mascarenhas et al., 2023).